The conversation is about using topical melatonin or zix for hair loss without affecting hormones. The user is seeking advice on which treatment is more effective.
A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.
The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.
The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.
KX-826 stopped hair loss for the user after stopping finasteride due to mild side effects. The user experienced mild headaches initially with KX-826, which resolved after a few days.
The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.
The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.
Nanoxidil is considered to have better absorption and fewer side effects than minoxidil, with added DHT blockers. The user is questioning if switching to the more expensive Spectral.DNC-N is worthwhile compared to cheaper options like Kirkland minoxidil.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
A user is asking if Minoboost F, a topical solution with 5% Minoxidil and 0.1% Finasteride, is effective or a scam due to the lack of online reviews. They seek opinions and reviews from others.
The user discusses using compounded oral minoxidil due to the ineffectiveness and inconvenience of topical minoxidil for diffuse thinning. They question the efficacy of compounded minoxidil compared to original tablet forms and express concerns about the importance of excipients and binders.
A 32-year-old male experienced erectile dysfunction and decreased libido after using oral dutasteride and minoxidil for hair loss. He is considering switching to topical alternatives like Xyon dutasteride or RU58841 to reduce side effects.
Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.
KX-826 is being considered as a potential alternative to finasteride for hair loss, but it is not expected to be more effective. Combining KX-826 with finasteride and minoxidil may provide better results than using it alone.
The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.
A satirical discussion on using minoxidil and finasteride in unconventional ways, including mixing them into drinks and other humorous methods. The conversation also touches on the potential health risks of minoxidil.
KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.
The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.
The conversation is about concerns regarding starting finasteride for AGA, with a preference for topical finasteride due to worries about oral side effects. The user is considering adding oral minoxidil later due to an allergy to topical minoxidil.
The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.
Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.
Aminexil, nanoxidil, stemoxydine, and kopexil are discussed as alternatives to minoxidil for hair growth, with concerns about dependence. Minoxidil is noted for its effectiveness in transitioning hair growth phases, but dependence is mainly linked to androgenic alopecia.
The conversation discusses hair regrowth progress using 1mg oral finasteride and 5mg oral minoxidil daily over three years. Concerns about potential heart risks from minoxidil dosage are raised, with suggestions to consult a doctor and consider reducing the dose.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.